2015-08-012024-05-13https://scholars.lib.ntu.edu.tw/handle/123456789/644958摘要：小細胞肺癌是非常惡性的癌症之一，它的特色是很早期就有轉移的徵兆，對於化學治療的反應極佳。 但是小細胞肺癌非常容易復發，而且很快就會產生抗藥性。有效的藥物只有幾種，因此整體而言， 小細胞肺癌的預後比分小細胞肺癌還要差。在現今標靶藥物的時代，尚無有效的標靶藥物。而上皮 生長因子接受器突變的肺腺癌病人，在接受標靶藥物後會有近5%的病人產生小細胞肺癌的轉變。 這些帶有突變的小細胞肺癌標靶藥物是沒有效果。目前的研究突變肺腺癌轉變成小細胞肺癌，都是 臨床觀察的結果，到底這些帶有突變的小細胞肺癌與傳統的小細胞肺癌有何差異，目前仍不清楚。 在我們實驗室利用原代培養，已有三株帶有上皮生長因子接受器突變的小細胞肺癌，這些全是從突 變肺腺癌病人接受標靶治療後轉變成小細胞肺癌的檢體培養而成。比較有趣的是，其中兩株有所謂 異質性的現象，可以分為平貼及懸浮生長，利用CD44表面標誌，能將平貼的細胞分離出來。在本 研究我們希望針對突變小細胞肺癌作進一步的分析，比較與傳統小細胞肺癌的差異。另外也想利用 現有的藥物篩選出有效的治療藥物。<br> Abstract: Small cell lung cancer (SCLC) is an aggrasive malignancy characterized with early metastases and initial response to chemotherepy. However, the prognosis is poor because of early relapse and resistant to chemotherapy. Several acquired resistant mechanisms of epidermal growth factor receptor (EGFR) activating mutation of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors (TKIs) therapy have been reported. SCLC transformation (less than 5%) has been reported as one of resistant mechanisms and these transformation cells maintained the EGFR mutation. All the information of SCLC transformation was from the surgical or biopsy specimens. The difference between these transformed EGFR mutation (+) SCLC and traditional EGFR mutation (-) SCLC is still unknown. We had established three EGFR mutation (+) SCLC cell lines. All of them came from the patients who had EGFR activating mutation and received EGFR-TKI. Heterogeneity with attached and sphere-forming morphology was found in two of these 3 cell lines and attached morphology could be enriched by CD44 marker. In this study, we want to characterize these EGFR mutation (+) cells. We will also compare these cells and EGFR mutation (-) SCLC. Identification the possible sensitive drugs for these cells is another aim.小細胞肺癌表皮生長因子接受器異質性細胞株Small cell lung cancerEGFR mutationheterogeneitycell lines